GlassScriptPhysician profile
Lori T Jordan
NPI 1609939271
$7,332.94
in general payments reported to CMS, 2019-2025
30 companies · $2,697 in 2025
The $2,697 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $947 · 2023: $1,854 · 2024: $1,501 · 2025: $2,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,956 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,955.65 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,431.91 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $780.07 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $676.01 | 2023-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $564.88 | 2022-2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $495.85 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $487.86 | 2022-2025 | Tezspire, Farxiga, Fasenra |
| Amgen INC. | $348.56 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $341.42 | 2025 | Wegovy, Ozempic |
| Scpharmaceuticals INC. | $334.69 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.59 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $236.30 | 2022-2025 | Eliquis, Camzyos |
| Vifor Pharma, INC. | $202.05 | 2023-2025 | Veltassa |
| Glaxosmithkline, LLC. | $164.51 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $134.47 | 2025 | Zepbound |
| Genzyme Corporation | $125.00 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $118.79 | 2024-2025 | Onpattro, Amvuttra |
| Grifols USA, LLC | $112.50 | 2025 | Prolastin-C Liquid |
| Pfizer INC. | $110.92 | 2022-2025 | |
| Philips North America LLC | $70.73 | 2025 | Vest Therapy Und, Coronary Other |
| Kiniksa Pharmaceuticals International, Plc | $60.06 | 2024 | Arcalyst |
| Watermark Medical, INC. | $52.63 | 2024-2025 | |
| Pulmonx Corporation | $46.32 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Calliditas Therapeutics US INC. | $45.89 | 2024 | |
| Merck Sharp & Dohme LLC | $41.97 | 2023 | Verquvo |
| Ani Pharmaceuticals, INC. | $37.08 | 2024-2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $19.71 | 2023 | Injectafer |
| Mannkind Corporation | $16.04 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.95 | 2025 | Aralast |
| Travere Therapeutics, INC. | $13.33 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $12.85 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.